Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28493
Full metadata record
DC FieldValueLanguage
dc.contributor.authorParakh, Sagun-
dc.contributor.authorNicolazzo, Joseph-
dc.contributor.authorScott, Andrew M-
dc.contributor.authorGan, Hui K-
dc.date2021-
dc.date.accessioned2022-01-10T03:25:19Z-
dc.date.available2022-01-10T03:25:19Z-
dc.date.issued2021-12-03-
dc.identifier.citationFrontiers in Oncology 2021; 11: 718590en
dc.identifier.issn2234-943X-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28493-
dc.description.abstractGlioblastoma (GBM) is an aggressive and fatal malignancy that despite decades of trials has limited therapeutic options. Antibody drug conjugates (ADCs) are composed of a monoclonal antibody which specifically recognizes a cellular surface antigen linked to a cytotoxic payload. ADCs have demonstrated superior efficacy and/or reduced toxicity in a range of haematological and solid tumors resulting in nine ADCs receiving regulatory approval. ADCs have also been explored in patients with brain tumours but with limited success to date. While earlier generations ADCs in glioma patients have had limited success and high toxicity, newer and improved ADCs characterised by low immunogenicity and more effective payloads have shown promise in a range of tumour types. These newer ADCs have also been tested in glioma patients, however, with mixed results. Factors affecting the effectiveness of ADCs to target the CNS include the blood brain barrier which acts as a physical and biochemical barrier, the pro-cancerogenic and immunosuppressive tumor microenvironment and tumour characteristics like tumour volume and antigen expression. In this paper we review the data regarding the ongoing the development of ADCs in glioma patients as well as potential strategies to overcome these barriers to maximise their therapeutic potential.en
dc.language.isoeng-
dc.subjectantibody drug conjugates (ADC)en
dc.subjectbiomarkersen
dc.subjectblood brain barrieren
dc.subjectglioblastomaen
dc.subjectgliomaen
dc.subjectmolecular imagingen
dc.subjecttumour microenvironmenten
dc.titleAntibody Drug Conjugates in Glioblastoma - Is There a Future for Them?en
dc.typeJournal Articleen
dc.identifier.journaltitleFrontiers in Oncologyen
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationMedical Oncologyen
dc.identifier.affiliationMolecular Imaging and Therapyen
dc.identifier.affiliationDrug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Heidelberg, VIC, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34926242/en
dc.identifier.doi10.3389/fonc.2021.718590en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3891-2489en
dc.identifier.orcid0000-0002-6656-295Xen
dc.identifier.orcid0000-0001-7319-8546en
dc.identifier.pubmedid34926242-
local.name.researcherGan, Hui K
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Nov 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.